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Aneuploidy, the presence of an abnormal number of chromosomes, is a major cause of early
pregnancy loss in humans. Yet, the developmental consequences of specific aneuploidies
remain unexplored. Here, we determine the extent of post-implantation development of
human embryos bearing common aneuploidies using a recently established culture platform.
We show that while trisomy 15 and trisomy 21 embryos develop similarly to euploid embryos,
monosomy 21 embryos exhibit high rates of developmental arrest, and trisomy 16 embryos
display a hypo-proliferation of the trophoblast, the tissue that forms the placenta. Using
human trophoblast stem cells, we show that this phenotype can be mechanistically ascribed
to increased levels of the cell adhesion protein E-CADHERIN, which lead to premature dif-
ferentiation and cell cycle arrest. We identify three cases of mosaicism in embryos diagnosed
as full aneuploid by pre-implantation genetic testing. Our results present the first detailed
analysis of post-implantation development of aneuploid human embryos.
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Human fecundity is remarkably low. It is currently believedthat aneuploidy is one of the major limitations of humanreproduction, accounting for approximately 50% of early
pregnancy losses1–4. Moreover, aneuploidy rates are remarkably
high in in vitro fertilized human embryos, with up to 50% of
embryos diagnosed as aneuploid based on preimplantation
genetic testing for aneuploidies (PGT-A)5–7. Aneuploidy may
lead to implantation failure, miscarriage, as well as congenital
defects8. Since very little is known about the impact of specific
aneuploidies during the early stages of human embryo develop-
ment, the point at which embryos with aneuploid cells die
remains unclear. This lack of knowledge is largely due to the
technical challenges in studying human embryo development
beyond implantation (day 7)9, a period that entails intensive
growth, morphogenetic remodeling and changes in stem cell
identity and fate10. Recent technical advances have allowed
human embryos to develop beyond day 7 and up to day 12/13
in vitro, in the absence of maternal tissues11,12. Embryos cultured
in this system recapitulate the major morphological transforma-
tions of in vivo developing embryos, such as separation of the
inner cell mass (ICM) into the epiblast that will give rise to the
embryo proper and the hypoblast that will give rise to the yolk
sac, formation of the amniotic and yolk sac cavity, and differ-
entiation of the trophoblast, the tissue that will form the
placenta11,12. Therefore, this culture method offers an unprece-
dented opportunity to characterize the early post-implantation
development of aneuploid human embryos in vitro.
Here, we aimed to characterize the developmental con-
sequences of specific whole chromosome aneuploidies during
human embryo development beyond the blastocyst stage. We
restricted our analyses to embryos that reached the blastocyst
stage in the appropriate timing to uncover phenotypes of early
post-implantation stages. Our results show that monosomy 21
embryos are 10 times more likely to arrest in culture than euploid
embryos, and trisomy 16 embryos present a hypoproliferation
defect specific of the trophoblast. Mechanistically, studies using
human trophoblast stem cells (TSCs) indicate that increased
levels of the cell adhesion protein E-CADHERIN, which is located
in chromosome 16, lead to cell cycle arrest and premature dif-
ferentiation. Moreover, we uncovered three cases of mosaicism in
embryos that were initially diagnosed by PGT-A as fully aneu-
ploid, highlighting the potential of our human embryo platform
to determine the extent of genetic mosaicism, and its influence on
post-implantation human development.
Results
Preimplantation development of aneuploid human embryos.
We first sought to investigate the impact of specific aneuploidies
on human preimplantation development. To this end, we assessed
the karyotype of human embryos when they reached the blas-
tocyst stage, as determined by PGT-A. Among 35,171 embryos
collected in a single center where PGT-A was offered to all
women (avoiding selection bias), we analyzed 9803 embryos that
showed single chromosomal aneuploidy, for which 4,712 were
autosomal monosomies, 4,717 were autosomal trisomies and 374
were sex chromosome aneuploidies and compared them with
25,368 euploid blastocysts. In our analyses, we included only full
chromosomal aneuploidies involving a single chromosome and
therefore all diagnosed mosaic or segmental aneuploidies were
excluded. Similarly, we excluded complex aneuploidies involving
more than one chromosome.
Our analyses revealed that the most common aneuploidies
involved chromosomes 15, 16, 21, and 22 (Fig. 1a). Since the time
taken to develop to blastocyst stage provides a readout of
successful preimplantation development, we categorized the
embryos into two groups: (1) embryos that reached the blastocyst
stage after 5 days (n= 13,358 embryos) and (2) embryos that
reached the blastocyst stage only after 6 days in culture (n=
21,439 embryos). We found that the proportion of embryos with
single chromosomal gain or loss that reached the blastocyst stage
only on day 6 was significantly higher than euploid embryos
(Fig. 1b). Although most aneuploidies had an effect on the time
needed to reach the blastocyst stage, the loss of a copy of
chromosome 3 or 6 or the gain of additional copies of
chromosomes 6, 8, 11, 12, or 20 resulted in the greatest
consequence for development to the blastocyst stage (Fig. 1b;
Supplementary Fig. 1). Similarly, the odds ratio of having a better
blastocyst expansion score (an indicator of blastocyst quality) at
day 5 was lower for embryos with single chromosomal
aneuploidy than euploid embryos (Fig. 1c). Monosomic aneu-
ploidies affected the day 5 expansion more severely than trisomic
aneuploidies (Fig. 1c).
Trisomy 15 embryos were similar to euploid embryos in their
ability to reach the blastocyst stage by day 5 and showed similar
expansion scores compared to euploid embryos (Fig. 1b, c).
Similarly, trisomy 16, trisomy 21 and monosomy 21 embryos
showed minimal developmental delay compared to euploid
embryos (Fig. 1b, c). These results indicate that all chromosomal
aneuploidies can reach the blastocyst stage, albeit at different
times and morphological properties.
Post-implantation development of aneuploid human embryos.
Next, we analyzed the extent to which particular aneuploidies
would lead to developmental differences during early post-
implantation stages, as approximately 30% of human pregnancies
are estimated to be lost at this stage8. To do so, we took advantage
of our recently established method to grow human embryos
beyond implantation in vitro11,12 (see “Methods”, Fig. 2a). We
selected good quality blastocysts based on the morphological
Gardner criteria13, which classifies blastocyst quality based on
expansion, from 1 (early blastocyst, with a cavity less than half the
embryo volume), to 6 (late blastocyst that has already hatched
from the zona pellucida to initiate implantation), and ICM/tro-
phoblast grade, from A (many cells), to C (very few cells). Out of
the 163 embryos we thawed, 152 exhibited A- or B-grade, and
only 11 exhibited a C-grade ICM and/or trophoblast. After
thawing, human blastocysts were first cultured for 24 h to allow
recovery and hatching from the zona pellucida. From 163 thawed
embryos, 2 embryos were lost during this procedure, and 26 had
to be excluded as they did not hatch (Supplementary Table 1).
This further decreased the number of C-grade blastocysts used in
this study to 6. After hatching, embryos were transferred to the
post-implantation in vitro culture (IVC) medium and allowed to
develop for 3 days, at which point they were fixed and analyzed.
We could distinguish three different categories of embryos based
on the development of the embryonic and extra-embryonic
lineages, assessed by the expression of specific molecular markers.
Embryos in the first category established OCT4+ embryonic
epiblast (precursor of the fetus and amnion), GATA6+ extra-
embryonic hypoblast (precursor of the yolk sac), and OCT4-
GATA6- extra-embryonic trophoblast (precursor of the placenta).
We, therefore, conclude that embryos in this category present a
normal morphology and maintain the three main lineages of the
blastocyst (these embryos were classified as all lineages). The
second category of embryos did not establish either epiblast or
hypoblast or both (these embryos were termed no ICM). The
third category comprised embryos in which development was
arrested (these embryos were termed dead/arrested) (Supple-
mentary Table 2).
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Fig. 1 Preimplantation development of aneuploid human embryos. a Prevalence of individual single chromosome aneuploidies among all embryos with
single chromosome aneuploidy (n= 9,429 embryos). b Odds ratios of embryos developing to the blastocyst stage by day 6 rather than day 5 for single
chromosome gain or loss (n= 9,429 embryos) as compared to euploid embryos (n= 25,368). Error bars represent 95% profile likelihood confidence
intervals. Blue line represents odds for euploid embryos. Confidence intervals, p values and the specific number of embryos analyzed per genotype is shown
in the Source Data file. c Odds ratios of embryos having a higher day 5 expansion score for single chromosome gain or loss (n= 9,429 embryos) as
compared to euploid embryos (n= 25,368). Error bars are 95% profile likelihood confidence intervals. Blue line represents odds for euploid embryos.
Orange bar represents gain of chromosome (trisomy) while cyan bar represents loss of chromosome (monosomy). Confidence intervals, p values and the
specific number of embryos analyzed per genotype is shown in the Source Data file. *p < 0.05, **p < 0.01, ***p < 0.001. Source data are provided as a
Source Data file.
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We first analyzed whether in the embryos used in this study the
quality of the ICM and/or trophoblast influences early post-
implantation development. We focused on A- and B- grade
blastocysts, as we did not have enough C-grade blastocysts for
comparison. We found that A- and B- grade blastocysts develop
similarly up to day 9 (Supplementary Fig. 2a and 2b. n= 54
grade-A and n= 60 grade-B embryos (panel a) and n= 59 grade-
A and n= 54 grade-B embryos (panel b)). We also analyzed
whether the blastocyst expansion rate has any influence upon
subsequent development. While embryos with an expansion score
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of 4 and 5 showed a similar developmental potential, embryos
with an expansion score of 6 presented a slightly higher incidence
of developmental arrest (Supplementary Fig. 2c. n= 59 grade 4,
n= 51 grade 5 and n= 16 grade 6 embryos). Previous studies
have indicated that implantation and pregnancy rates are higher
when embryos reach the blastocyst stage on day 5 compared to
embryos establishing the blastocyst stage at day 614. Interestingly,
we noted that 75% of embryos with an expansion score of 6
reached the blastocyst stage on day 6 (in comparison with 0% for
an expansion score of 4 and 6% for a score of 5). Therefore, we
next analyzed whether there were any differences in the
developmental competency of day 5 and day 6 blastocysts
in vitro. We found that day 6 blastocysts showed more limited
development compared to day 5 blastocysts: while 44% of
embryos that reached the blastocyst stage at day 5 developed to
day 9 with all lineages preserved and presented a normal
morphology, none of the embryos that reached the blastocyst
stage at day 6 presented a normal morphology at day 9
(Supplementary Fig. 2d and 2e. n= 16 day 5 and n= 14 day 6
embryos). Based on these findings, we limited all our subsequent
analyses to those embryos that reached the blastocyst stage by day
5. The specific criteria used for analysis (hatched day 5 blastocysts
with a good embryological score) allowed us to exclude embryos
that presented morphological alterations and/or delayed pre-
implantation development, although more subtle alterations
cannot be excluded.
For further study, we focused on embryos diagnosed as trisomy
21, trisomy 15, trisomy 16 and monosomy 21 as four examples of
aneuploidies that are commonly detected at the blastocyst stage
(Fig. 1a), have limited impact on pre-implantation development
(Fig. 1b, c), and yet lead to very distinct clinical phenotypes.
Trisomy 21 is the most common viable trisomy, which affects
approximately 1 out of 700 newborns15. Trisomy 15 and trisomy
16 typically lead to first trimester miscarriage16, where most
trisomy 16 abortions show empty sacs or minimal development
of the embryo, while trisomy 15 miscarriages have specific
craniofacial, limb and umbilical cord structural defects17,18. We
analyzed a total of 71 embryos with these specific aneuploidies:
trisomy 21 (14 embryos), trisomy 15 (16 embryos), trisomy 16
(24 embryos), and monosomy 21 (17 embryos) 9 days after
fertilization. In addition, we included 22 euploid embryos as
controls (Supplementary Table 2). We found blastocysts attached
to the dish at day 7-8, which was followed by trophoblast
expansion and growth (Supplementary Fig. 3a). We found that
attachment occurred irrespective of the genetic makeup of the
embryos, with nearly 100% efficiency (Supplementary Fig. 3b).
Following embryo development in culture revealed that monos-
omy 21 embryos exhibited a high rate of arrest by the end of the
9th day of culture, they were smaller in size and contained nuclear
debris, indicative of cell death (Fig. 2b, c). These results show that
the developmental potential of monosomy 21 embryos is already
decreased during the first days of post-implantation development,
even in those embryos that reach the blastocyst stage with the
appropriate morphology by day 5. These results are in agreement
with a report of defective monosomic embryo attachment
in vitro19, and with the notion that autosomal monosomies lead
to pre-clinical pregnancy loss, as they are rarely detected in first-
trimester miscarriages2,4,20,21. In contrast, we found that over the
first days of post-implantation development in vitro, trisomic
embryos developed similarly to euploid embryos (Fig. 2b, c). We
did not detect any significant differences in the in vitro
developmental potential of female and male embryos, either
during pre-implantation or early post-implantation development
(Supplementary Fig. 4a to 4e. n= 36 female and n= 56 male
embryos).
To characterize, in detail, subtle differences in development
beyond day 7, we next focused on the sub-group of embryos in
each karyotype that developed with apparently normal morphol-
ogy and preserved the three lineages of the blastocyst (the first
category of embryos: n= 10 euploid, n= 6 trisomy 21, n= 13
trisomy 15, n= 15 trisomy 16, and n= 7 monosomy 21
embryos). The first morphogenetic transformation of the
embryonic epiblast upon implantation is its polarization and
epithelialization leading to the formation of the amniotic cavity9,
which can be detected by the presence of the apical protein
Podocalyxin (PODXL)22,23. We did not observe any significant
differences in the efficiency of epithelialization and amniotic
cavity formation for the different karyotypes (Supplementary
Fig. 5a and 5b). Further analyses of total cell numbers revealed
that while trisomy 15 and trisomy 21 embryos did not show any
significant differences compared to control euploid embryos,
trisomy 16 and monosomy 21 embryos were significantly smaller
and had fewer total cells (Fig. 2d). Importantly, this decrease was
mainly due to a decrease in the number of trophoblast cells, as we
could not detect any significant differences in the number of
epiblast and hypoblast cells (Fig. 2e–g). The hypoplastic
trophoblast observed in trisomy 16 embryos could potentially
explain the intrauterine growth restriction and preeclampsia
commonly observed in cases of confined placental mosaicism of
trisomy 1617. Overall, these results indicate that trisomy 16 and
monosomy 21 embryos are already compromised during the first
days of post-implantation development.
Identification of misdiagnosed embryos by PGT-A. We hypo-
thesized that the specific trophoblast phenotype of some
monosomy 21 embryos in the absence of an epiblast and hypo-
blast phenotype could be due to mosaicism. To test this
hypothesis, we manually dissected fixed day 9 embryos into
between two and seven pieces based on the size of the embryo,
and then lysed, pre-amplified, and assessed chromosome copy
number using targeted next-generation sequencing (tNGS). The
chromosome copy number results were compared with previous
PGT-A results for the same embryo performed on day 5 using
either 24 chromosome polymerase chain reaction (PCR) (9 out of
93 embryos), microarray (2 out of 93 embryos), or tNGS (82 out
of 93 embryos), as we have previously described24,25
Fig. 2 Early post-implantation development of aneuploid human embryos. a Schematic representation of the methodology used in this study.
b Immunostaining of human embryos cultured until day 9. Representative images of each karyotype are shown. Scale bars, 50 μm. c Developmental
phenotypes of embryos from panel (b). The number of embryos per category is indicated. Chi-square test, **p= 0.0018, *p= 0.0105, ns nonsignificant.
d Total number of cells in embryos with all lineages from panel (b). Each dot represents an individual embryo. n= 10 euploid, 6 trisomy 21, 13 trisomy 15, 15
trisomy 16 and 7 monosomy 21 embryos. One-way ANOVA with a multiple comparisons test, **p= 0.0011 (trisomy 16) and **p= 0.0027 (monosomy 21).
e–g, Number of epiblast (e), hypoblast (f), and trophoblast (g) cells in embryos with all lineages from panel (b). Each dot represents an individual embryo,
with green for epiblast, red for hypoblast and blue for trophoblast cell counts. n= 10 euploid, 6 trisomy 21, 13 trisomy 15, 15 trisomy 16 and 7 monosomy 21
embryos. One-way ANOVA with a multiple comparisons test, **p= 0.0015, ***p= 0.0005, ns nonsignificant. All error bars represent s.e.m. four
independent experiments. ICM inner cell mass, tNGS targeted next generation sequencing, IVC in vitro culture. Source data are provided as a Source
Data file.
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(Supplementary Table 2). The three sections obtained from
embryo 89 (identified as 45,XX,−21 based on trophoblast biopsy
at day 5 and PGT-A by tNGS) showed 45,XX,−21, 46,XX, and 45,
XX,−21 (Fig. 3a, b), confirming the mosaicism for loss of chro-
mosome 21 and indicating the higher developmental potential of
mosaic embryos (Fig. 3a), in agreement with previous studies of
mosaic mouse and human embryos19,26,27. These results are also
in agreement with observations indicating that trisomic embryos
can give rise to trisomic human embryonic stem cells (ESCs),
whereas euploid human ESCs can be obtained from monosomic
embryos due to mosaicism28,29. Embryo 142, which was diag-
nosed as 45,XX,−21 based on trophoblast biopsy at day 5 and
a b tNGS results on day 9
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PGT-A by tNGS, arrested in culture. Chromosome copy number
analysis of this embryo on day 9 was consistent with the previous
PGT-A result (Fig. 3c, d).
We identified two additional non-concordant cases. Embryo 86
was identified as 47,XX,+21 based on PGT-A by tNGS on day 5,
whereas tNGS on day 9 showed a mosaic of trisomy 21 and
monosomy 21 cells (Fig. 3e, f), indicative of mitotic nondisjunc-
tion. The presence of monosomy 21 cells could explain the arrest
of the embryo upon culture to day 9. Embryo 101 was diagnosed
as 47,XX,+16 on day 5 by tNGS, and at day 9 was dissected into 6
pieces, all of which proved to be 46,XX, suggesting that the
initial PGT-A result could represent a misdiagnosis (Fig. 3g, h).
This result could also be explained by selective elimination of
the aneuploid cells by programmed cell death as the embryo
developed beyond day 5, as previously shown to occur in
mouse embryos26,30. Alternatively, if the aneuploid cells were
restricted to the mural trophoblast these cells could have been
removed during the biopsy procedure at day 5. The copy number
analyses of the remaining post-implantation embryos (26 out of
29) were consistent with prior PTG-A results (Supplementary
Fig. 6a–h).
Functional characterization of E-cadherin in TSCs. Next, we
wished to explore the mechanism leading to the trophoblast
hypoproliferation in trisomy 16 embryos that we detected above.
We hypothesized that increased expression of a gene(s) located in
chromosome 16 could lead to the above-mentioned phenotype.
This turned our attention to the chromosome 16 gene CDH1,
which encodes the cell-cell adhesion protein E-cadherin (ECAD).
ECAD is a transmembrane protein that promotes adhesion
between epithelial cells and regulates cell shape31. Moreover, by
binding intracellularly to the WNT signaling pathway component
β-catenin, it modulates the levels of WNT signaling, affecting
cellular identity and behavior32. To test this hypothesis, we first
attempted to derive trisomy 16 human ESCs, with the final aim of
differentiating them to trophoblast and decreasing the levels of
ECAD. However, it was not possible to derive trisomy 16 human
ESC lines from trisomy 16 human blastocysts, while derivation of
euploid human ESC lines from euploid blastocysts of equal
quality was successful under the same derivation conditions
(Supplementary Fig. 7a). As an alternative, and to test whether
increased levels of ECAD could lead to trophoblast differentiation
and cell cycle arrest, we decided to use human TSCs33 as a model
system. Importantly, human TSCs show transcriptional similarity
to early post-implantation cytotrophoblast34. In parallel, we used
human ESC cultures to model the post-implantation epiblast35.
We first created stable human TSC and ESC lines that
overexpress an ECAD–EGFP fusion protein upon addition of
doxycycline (DOX) to the medium (see “Methods”). All of the cell
lines were confirmed to be euploid to ensure observed phenotypes
were specific to overexpression of ECAD (Supplementary
Fig. 7b–e). As a control, we validated that DOX administration
in non-transfected cells did not affect proliferation or expression
of stemness markers (Supplementary Fig. 8a–g). We then focused
our attention on the ECAD–EGFP transfected cells and
performed a time-course analysis of the effects of DOX
administration. We found that already after 48 h of DOX
addition to the medium, human TSCs transfected with
ECAD–EGFP underwent a morphological change, from regular,
cuboidal and epithelial, to irregular, flat, and disorganized cells
(Supplementary Fig. 9a). After 1 week in the presence of DOX,
they stopped proliferating and only a few giant cells could be
observed in the dish (Supplementary Fig. 9a). In parallel, we
performed equivalent experiments in human ESCs and observed
no morphological alterations upon DOX administration (Supple-
mentary Fig. 9a). Importantly, ECAD expression was upregulated
in both ESCs and TSCs upon addition of DOX (Supplementary
Fig. 9b, c). To characterize this phenotypic change in more detail,
we analyzed the levels of the TSC marker GATA3 upon addition
of DOX by immunofluorescence. In accordance with the observed
morphological change, GATA3 levels significantly decreased
upon ECAD–EGFP upregulation (Fig. 4a, b). This was accom-
panied by an increase in the percentage of multinucleated cells
(Supplementary Fig. 9d), and a decrease in proliferation, as
indicated by the decreased numbers of mitotic cells labeled by
phospho-Histone H3 (pH3) staining (Fig. 4c). Interestingly,
ECAD–EGFP upregulation in ESCs did not affect the levels of the
pluripotency marker NANOG and only led to a mild decrease in
proliferation (Fig. 4e–g). These findings were validated by real-
time PCR (RT-PCR); while pluripotency factors NANOG and
OCT3/4 did not change upon ECAD–EGFP overexpression in
ESCs (Fig. 4h), TSCs overexpressing ECAD–EGFP showed a
marked upregulation of the differentiation markers SDC1 and
HLA-G (Fig. 4d). We found that the levels of AXIN2, a WNT
target gene, were significantly decreased in ECAD–EGFP over-
expressing TSCs but not ESCs (Fig. 4d, h). To further confirm the
effect of ECAD overexpression on TSCs, we sought a second cell
type to model the human periimplantation and post-implantation
trophoblast. To this end, we converted ESCs that overexpress
ECAD in the presence of DOX to TSCs (cTSCs)36. Forty-eight
hour following addition of DOX to the media, these cells
exhibited an increase in HLA-G expression and a differentiated
morphology (Supplementary Fig. 9e–g). These findings indicate
that ECAD overexpression leads to increased differentiation, cell
cycle arrest, and decreased WNT activity in human TSCs.
The level of ECAD overexpression with the addition of DOX
(1 μg mL−1) to TSCs was 200 to 300-fold, which is above the
physiological level to be expected with a single additional allele.
To address this, we administered lower dosages of DOX and
found that a concentration of 10 ng mL−1 over 3 days achieved a
1.6-fold overexpression of ECAD (Fig. 5a). At this level of
overexpression, the relative expression of differentiation markers
SDC1 and HLA-G increased, the levels of the trophoblast marker
GATA3 decreased, the proportion of SDC1+ cells and multi-
nucleated cells significantly increased, and the proportion of pH3-
positive cells significantly decreased (Fig. 5b–f). This indicates
that a physiological upregulation of ECAD is sufficient to induce
premature differentiation and cell cycle arrest of human TSCs.
Overexpression of ECAD resulting in increased TSC differ-
entiation was surprising as ECAD expression decreases upon
Fig. 3 Chromosome copy number analysis of post-implantation embryos cultured in vitro until day 9. a Immunostaining of mosaic monosomy
21 embryo (#89, diagnosed as monosomy 21 on day 5) showed normal development of hypoblast and epiblast with limited development of
trophoblast. b Chromosome copy number analysis from two of the three dissections of the fixed embryo (#89) consistent with mosaic monosomy 21.
c Immunostaining of arrested monosomy 21 embryo (#142, also diagnosed as monosomy 21 on day 5). d Chromosome copy number analysis from the
dissections of the fixed dissected embryo (#142) confirmed the previous PTG-A result from day 5 embryo biopsy (45,XX,−21). e Immunostaining of a
mosaic trisomy 21 and monosomy 21 embryo (#86, diagnosed as trisomy 21 on day 5) showed arrested development. f Chromosome copy number
analysis showed the presence of monosomy 21 cells. g Immunostaining of a euploid day 9 human embryo (#101, diagnosed as trisomy 16 on day 5).
h Chromosome copy number analysis was consistent with euploidy. All scale bars, 50 μm. tNGS targeted next-generation sequencing.
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cytotrophoblast differentiation into extravillous trophoblast
in vivo37–39. We, therefore, asked whether decreasing ECAD
levels would be sufficient to affect cell fate. Transient transfection
of CDH1 (ECAD) siRNA resulted in a tenfold decrease in
CDH1 expression compared with control siRNA (Fig. 5g)
However, this resulted in no significant difference in expression
of cytotrophoblast markers GATA3, ELF5, or TP63 or in
expression of differentiation markers HLA-G or SDC1 (Fig. 5h,
k). In addition, despite the decrease in ECAD expression, there
was no change in AXIN2 expression, suggesting that the activity
of the WNT signaling pathway was unchanged (Fig. 5j). These
results suggest that the observed decrease in ECAD expression
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upon cytotrophoblast differentiation in vivo may not play a causal
role in cell fate determination.
Trophoblast differentiation in trisomy 16 embryos. To validate
our findings in human TSCs in human embryos, we next cultured
in vitro euploid and trisomy 16 embryos up to day 9 and analyzed
the levels of ECAD, SDC1 and pH3 in their trophoblast. We
found that the trophoblast of trisomy 16 embryos presented
increased levels of ECAD, increased SDC1 expression, increased
numbers of multinucleated trophoblast cells, and a decrease in the
percentage of pH3-positive mitotic cells (Fig. 6a–e. n= 8 euploid
and n= 7 trisomy 16 embryos), in agreement with our previous
findings. In summary, our results indicate that the increased
levels of ECAD in trisomy 16 embryos contribute to the differ-
entiation and hypoproliferation of the trophoblast compartment
without causing major phenotypic changes in epiblast cells at
these stages.
Discussion
Here, we aimed to characterize the development of aneuploid
human embryos in vitro with the goal of uncovering the cellular
and developmental defects of specific aneuploidies and the
molecular mechanisms responsible. To this end, we first com-
pared human blastocysts diagnosed with single aneuploidy to
those diagnosed as euploid for their potential for preimplantation
development. We found that gain or loss of chromosomes 15, 16,
21, and 22 are most frequently diagnosed in blastocysts, sug-
gesting that development up to the blastocyst stage is more tol-
erant of errors involving those chromosomes in agreement with
previous results40.
We next focused our attention on particular aneuploidies that
are common and cause minimal impact on preimplantation
development (trisomy 15, trisomy 16, trisomy 21, and monosomy
21), and selected those human embryos that reached the blas-
tocyst stage with the correct morphology and at the appropriate
timing. Even when narrowing down our analysis to this popu-
lation of good prognosis embryos, our results showed that
monosomy 21 embryos are likely to arrest between day 7 and day
9. Upon implantation, the human embryo undergoes a dramatic
morphological remodeling, that is associated with an increase in
proliferation, cell fate specification events, and lineage commit-
ment10. It is therefore likely that embryos lacking an autosome
cannot cope with the demands of this developmental phase.
Previous reports have shown that monosomic blastocysts graded
as high quality already present epigenetic alterations such as
hypomethylation, and genetic instability41, which could con-
tribute to their diminished developmental potential beyond
implantation. Another study analyzed the in vitro attachment of
monosomic embryos as a readout of implantation development19
and found a significant decrease in attachment rates for mono-
somic embryos. Given that the authors pooled multiple mono-
somies together, their results may be confounded by the
differential phenotypes of specific monosomies. In this regard, we
did not detect any significant defect in attachment rates for
monosomy 21 embryos.
Surprisingly, a proportion of monosomy 21 embryos survived
up to day 9 but displayed a hypoproliferation defect of the tro-
phoblast. Our tNGS results from embryo 89 supports the notion
that this phenotype could be a consequence of genetic mosaicism,
which was not diagnosed by PGT-A at the blastocyst stage. Given
that the current technology does not allow us to separate cells
according to their tissue of origin to perform tNGS, it is impos-
sible to conclude whether all ICM-derived cells were euploid and
the aneuploid cells were restricted to the trophoblast-derived
tissues or mosaicism was also presented in the ICM-derived
lineages. In this regard, the fate of aneuploid cells in mosaic
human embryos remains unknown. Previous results from our lab
have shown that in mouse embryos aneuploid cells in the
embryonic epiblast present a higher rate of apoptosis than
aneuploid cells in the extra-embryonic tissues26,30. These results
rely on inducing aneuploidy by the drug reversine, which can
cause chaotic aneuploidies26. Interestingly, it has been reported
that while rates of aneuploidy between the trophoblast and ICM
are not significantly different at the blastocyst stage, aneuploid
cells are enriched in the trophoblast of in vitro cultured post-
implantation human embryos42. Moreover, mouse epiblast cells
at early post-implantation stages upregulate the expression of
proapoptotic genes, which leads to a lower apoptotic threshold in
embryonic versus extraembryonic cells in response to DNA
damage43,44. These studies highlight the different responses of
embryonic and extraembryonic cells to damage. However, whe-
ther there is a selective elimination of aneuploid cells in the
epiblast of post-implantation human embryos remain to be
addressed upon development of more advanced methodology.
We also analyzed the development of specific trisomies, namely
trisomy 21, trisomy 15, and trisomy 16. Although we did not
detect any significant morphological alterations in trisomy 21 and
trisomy 15 embryos, whether there are changes at the mRNA and
protein levels remains to be explored. In support of this notion,
previous reports have shown marked transcriptional alterations in
pre-implantation aneuploid human embryos42,45,46. Careful
analysis of trisomy 16 embryos revealed a marked hypoproli-
feration phenotype specific to the trophoblast. To study the
mechanisms behind this effect, we used human TSCs and ESCs as
models of the trophoblast and epiblast respectively. We found
Fig. 4 Characterization of ECAD-overexpressing human TSCs and ESCs. a Immunostaining of human TSCs transfected with a CDH1-EGFP expressing
plasmid. ECAD expression is triggered upon 1 µgmL−1 DOX addition. b Quantification of GATA3 levels in cells from panel (a). n= 2,052, 589, 285, and 136
cells per condition. Kruskal Wallis test, ****p < 0.0001. Data are shown in a box plot. Whiskers go from minimum to maximum values. The box extends
from the 25th to 75th percentile, and the middle line represents the median. c Percentage of phospho-HISTONE H3 (pH3) positive cells in cells from panel
(a). n= 2,789, 805, 156, and 183 cells per condition. Chi-square test, *p= 0.018. d RT-PCR analysis of SDC1, HLA-G, and AXIN2 levels in human TSCs that
were/were not transfected with a CDH1-EGFP expressing plasmid in the presence or absence of 1 µg mL−1 DOX. Each dot represents one sample. n=
4 samples per condition. One-way ANOVA with a multiple comparisons test, *p < 0.0479, **p= 0.0022. Error bars represent s.e.m. e Immunostaining of
human ESCs transfected with a CDH1-EGFP expressing plasmid. ECAD expression is triggered upon DOX addition. f Quantification of NANOG levels in cells
from panel (e). n= 2,980, 803, 1,080, and 1,829 cells per condition. Kurskal Wallis test, ns nonsignificant. Data are shown in a box plot. Whiskers go from
minimum to maximum values. The box extends from the 25th to 75th percentile, and the middle line represents the median. g Percentage of phospho-
HISTONE H3 (pH3) positive cells in cells from panel (e). n= 3,091, 717, 1,497, and 2,243 cells per condition. Chi-square test, ****p < 0.0001. h RT-PCR
analysis of NANOG, OCT3/4, and AXIN2 levels in human ESCs that were/were not transfected with a CDH1-EGFP expressing plasmid in the presence or
absence of 1 µg mL−1 DOX. Each dot represents one sample. n= 4 samples per condition. One-way ANOVA with a multiple comparisons test, ns
nonsignificant. All error bars represent s.e.m. three independent experiments (panels a–c, e–g) and two independent experiments (panels d and h). All
scale bars, 50 μm. Source data are provided as a Source Data file.
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that increased levels of ECAD lead to cell cycle arrest and dif-
ferentiation in TSCs. The observed effects were specific to TSCs,
as ESCs remain pluripotent in the presence of increased levels of
ECAD. However, upon conversion of ESCs to TS-like cells,
increased levels in ECAD resulted in an upregulation of the
differentiation marker HLA-G. In agreement with these findings,
a similar phenotype, specific to the trophoblast compartment, was
observed in trisomy 16 embryos.
The increased incidence of polyploid cells and the upregulation
of SDC1 and HLA-G upon ECAD overexpression are compatible
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with the terminal differentiation of TSCs into trophoblast giant
cells, although we cannot rule out the possibility that diverse
differentiated populations have been specified. WNT signaling is
fundamental for TSCs maintenance33. In the absence of WNT
signaling TSCs differentiate into HLA-G-positive extravillous
trophoblast cells33, precursors of trophoblast giant cells. Inter-
estingly, we observed decreased levels of the WNT target gene
AXIN2 upon ECAD upregulation. These observations suggest
that the increased levels of ECAD could sequester β-catenin away
from the nucleus (as observed in multiple other systems47–49),
and therefore lead to a decrease in WNT activity and premature
differentiation (Fig. 6f ). Overall, our results show that increased
levels of ECAD contribute to the hypoproliferation of trisomy 16
trophoblasts. We anticipate that additional changes in protein
levels and aneuploid-induced stresses may also contribute to the
early lethality of trisomy 16 embryos. To gain further mechanistic
understanding of how trisomy 16 affects embryo development we
attempted to establish trisomy 16 human ESCs. However, this
was not possible, indicating that there may be defects in trisomy
16 epiblast cells preventing robust human ESC derivation.
Therefore, whether additional proteins become misregulated in
trisomy 16 embryos, especially in the trophoblast compartment,
and contribute to the observed phenotype remains unknown.
In summary, our findings show that the IVC method of human
embryo culture is a bona fide platform to study early post-
implantation developmental competency, a developmental win-
dow that is not amenable to study in embryos developing in vivo.
Using this system, we have characterized the development of
embryos with specific aneuploidies up to day 9 and uncovered
tissue-specific alterations. Moreover, our results demonstrate that
the in vitro culture platform can be used to identify cases of
mosaicism and embryos misdiagnosed by PGT-A. This opens the
door for future studies aimed at determining the fate of aneuploid
cells during early post-implantation development, and the
developmental competency of mosaic embryos, a currently unmet
clinical need in human reproduction.
Methods
Ethics statement for human embryo experiments. Human embryos were ori-
ginally created for purposes of procreation. The study was approved by the Wes-
tern Institutional Review Board (Clinical IRB 20031397 and 20050731). Additional
ethical approval was obtained from the Human Biology Research Ethics Com-
mittee (University of Cambridge, HBREC.2017.24). Embryos used in this study
were obtained from patients undergoing IVF treatment at IVI-RMA. Informed
consent was obtained from all the couples that donated their surplus human
embryos.
For human ESC line derivations embryos were donated to the University of
Michigan under the category of not suitable for implantation, following PGT-A
and/or preimplantation genetic testing for monogenic diseases (PGT-M). Three
embryos (UM189-2; UM204-3; and UM230-1) were determined to be Trisomy 16,
and the other three embryos (UM161-2; UM178-1; UM207-4) were determined to
be euploid. Written informed consent for donation was obtained as outlined by
NIH guidelines, and human ESC line derivation (attempted and/or successful) was
performed under University of Michigan’s Institutional Review Board approved
study, “Derivation of human Embryonic Stem Cells” (HUM00028742).
Assessment of pre-implantation aneuploid embryos. All embryos (n= 35,171)
generated at Reproductive Medicine Associates of New Jersey (RMANJ) in New
Jersey, USA between January 2011 and August 2017 were included in the study. A
total of 9,429 embryos diagnosed with a single chromosome aneuploidy involving
an autosome and 374 sex chromosome aneuploid embryos were compared to 25,368
euploid embryos for their pre-implantation development characteristics. PGT-A
(microarray, qPCR or NGS-based, Supplementary Table 2) was carried out at
Foundation for Embryonic Competence (FEC, Basking Ridge, NJ, USA) from tro-
phoblast biopsies obtained on day 5 or 6 of in vitro culture, depending on when the
embryo reached a developmental stage considered adequate for biopsy. An
expansion score (an integer between 0 and 6) was given to each of these embryos on
day 5 based on the previously published criteria13. A higher score corresponds to an
embryo that is more expanded, completely hatched and/or cellular. Logistic
regression models were used to assess the odds ratio of embryos being biopsied on
day 6 (i.e., developed more slowly) vs. day 5 for each type of single chromosome
aneuploidy as compared to euploid embryos. Ordinal logistic regression models
were used to obtain the odds ratio of embryos having a higher day 5 expansion score
for each type of single chromosome aneuploidy as compared to euploid embryos.
Analysis was carried out in R version 3.5.0 with MASS package version 7.3-49.
Human embryo thawing. All blastocysts used in this study had undergone assisted
hatching on day 3 post-fertilization, trophoblast biopsy after reaching the blas-
tocyst stage on day 5 or 6, PGT-A, and cryopreservation. Embryo quality was
assessed prior to embryo freezing using Gardner criteria13. Embryos were pipetted
using STRIPPER pipettes (Cooper Surgical, US) with disposable plastic tips and
thawed using Cryotop Thawing Media Kit (Kitazato, USA). One day prior to
thawing the embryos, drops of the human embryo culture medium (Origio
Sequential Blast, REF83050010D) covered by mineral oil (Vitrolife, 506061) were
incubated in 21% O2/5% CO2 at 37 °C overnight. Dishes (35 mm, BD Falcon,
351008) with prewarmed TS solution and center-well dishes with DS, WS1 and
WS2 solutions (1 ml per well) were also prepared prior to starting the thawing
procedure. TS solution was prewarmed 2 h in a 37 °C incubator while DS, WS1,
and WS2 solutions were prewarmed in room temperature. The straw containing a
vitrified blastocyst-stage embryo was removed from the liquid nitrogen and was
opened according to manufacturer’s instructions. The straw was immediately
immersed in the prewarmed TS solution for 1 min; the embryo was located under
the dissection microscope and was transferred sequentially to the DS solution for
3 min, WS1 solution for 3 min and WS2 solution for 1 min at room temperature.
The embryo was then washed three times in drops of pre-equilibrated complete
human embryo culture medium and cultured in a drop of pre-equilibrated com-
plete human embryo culture medium for 24 h.
Human embryo culture beyond implantation in vitro. On the first day of the
experiment (in vitro culture day 0), IVC1 (Cell guidance system, M11–25) was
equilibrated in 21% O2/5% CO2 incubator at 37 °C for a minimum of 1 h, and
300 μL of the pre-equilibrated IVC1 per well was pipetted to an ibiTreat 8-well μ-
plate (Ibidi, 80826). The embryo was transferred into the ibiTreat 8-well μ-plate
and the plate was immediately placed in a 21% O2/5% CO2 incubator at 37 °C. On
the second day of in vitro culture, IVC2 (Cell guidance system, M12–25) was
placed in a 21% O2/5% CO2 incubator at 37 °C to equilibrate for a minimum of 1 h;
150 μL of IVC1 medium was removed from the well and 200 μL of pre-equilibrated
IVC2 was added. Similarly, until the culture was terminated, medium was changed
every day by removing 150 μL and adding 200 μL of pre-equilibrated IVC2
medium.
Fig. 5 Role of ECAD during trophoblast differentiation. a–c RT-PCR analysis of CDH1, SDC1, and HLA-G levels in human TSCs transfected with a CDH1-
EGFP expressing plasmid in the presence or absence of 10 ngmL−1 DOX. Each dot represents one sample. n= 3 samples for −DOX and 4 samples for
10 ngmL−1 DOX. Unpaired Student’s t test, CDH1 *p= 0.0131. SDC1 *p= 0.0357. HLA-G *p= 0.0634. d Immunostaining of human TSCs transfected with
CDH1-EGFP expressing plasmid in the presence or absence of 10 ngmL−1 DOX. n= 4 samples per condition. e Percentage of phospho-HISTONE H3 (pH3)-
positive cells, SDC1-positive cells, and multinucleated cells in human TSCs transfected with a CDH1-EGFP expressing plasmid in the presence or absence
of 10 ngmL−1 DOX. n= 743 and 1,675, 1,407 and 2,752, and 2,132 and 3,707 cells for each condition. Chi-square test, PH3+ ***p= 0.00321, SDC1+
****p= 0.0001, multinucleated ****p < 0.0001. f Quantification of relative GATA3 fluorescence from (d). n= 4,424 and 2,120 per condition. Unpaired
Student’s t test, ****p < 0.0001. g RT-PCR of CDH1 in cells transfected with control or CDH1 siRNA. Each dot represents one sample. n= 4 samples
for control siRNA and five samples fo CDH1 siRNA. Unpaired Student’s t test, ****p= 0.00000170. h Immunostaining of human TSCs transfected with
control or CDH1 siRNA. i Quantification of relative GATA3 levels from panel (h). n= 1,772 and 1,856 cells per condition. Unpaired Student’s t test, ns
nonsignificant, p= 0.331. j, k RT-PCR of SDC1, HLA-G, AXIN2, GATA3, TP63, and ELF5 in cells transfected with control or CDH1 siRNA. Each dot represents
one sample. n= 4 samples for control siRNA and 5 samples fo CDH1 siRNA. Unpaired Student’s t test, ns nonsignificant. All error bars represent s.e.m.
Scale bars, 50 µm two independent experiments (panels a, b, c, h, and i) and three independent experiments (panels d, e, g, j, and k). Source data are
provided as a Source Data file.
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Human ESC line derivation. All human ESC attempted derivations began with
vitrified day 5 cryopreserved human blastocyst. Following warming, blastocysts
were cultured for 23 h to allow re-expansion followed by microscopic laser-
isolation of the ICM of the day-6 blastocysts. Isolated ICMs were plated on inactive
Human Foreskin Fibroblasts (HFFs, Global Stem, GSC-3002) in human ESC-
Xeno-free Culture Media (Knock-out DMEM (Gibco, 10829) containing 20%
Knockout Serum Replacement (Gibco, 12618012), 1 mM Glutamax
(Gibco, 35050-061), 0.1 mM β-mercaptoethanol (Sigma-Aldrich, M6250), 10 mM
nonessential Amino Acid 100× (Gibco, 11140-05), and 4 ng ml−1 basic fibroblast
growth factor-Xeno-free (MilliporeSigma, GF003AF-100UG). The culture condi-
tions of cell expansion on HFFs were maintained at 5% CO2/5% O2/90% N2 at
37 °C for 5–7 days (passage 0; P0) until a pre-epiblast-like structure was identified
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and manually/mechanically split with glass microtools and passaged (P1) onto
fresh HFFs, with fresh media, under similar culture conditions. Attempted human
ESC derivation was performed with all six human embryos in the same time
period, with the same media/additive lot numbers, with the same lot of HFFs, and
by the same personnel to reduce inter-attempt variability. For the first 2–5 passages
epiblast-like structures and early expanding human ESCs were observed and
provided fresh media and additives every other day until manual/mechanical
passage onto fresh HFFs (approximately every 7 days). As human ESC lines were
established and expanding (P5–7), freeze backs were performed and human ESCs
were passaged onto feeder-free matrix, Matrigel (Corning, #354277) with mTeSR1
Media (StemCell Technologies, #85850), with culture conditions of 5% CO2/20%
O2/remainder air at 37 °C to allow continued expansion and characterization.
Human ESC lines were characterized for pluripotency, genetic composition, mul-
tilineage identification (endoderm, mesoderm, and ectoderm) of resulting embry-
oid bodies, and lack of mycoplasma contamination as indicated for other UM-
human ESCs previously produced and published50.
Human stem cell culture. H9 human ESCs were kindly provided by Ludovic
Vallier (Stem Cell Institute, UK), under an agreement with WiCell. Experiments
with human ESCs were approved by the UK Stem Cell Bank Steering Committee
and comply with the regulations of the UK Code of Practice for the Use of Human
Stem Cell Lines. CT human TSCs were kindly provided by Hiroaki Okae and
Takahiro Arima (Tohoku University Graduate School of Medicine, Japan)33.
Human ESCs were cultured in matrigel-coated plates in mTESR medium
(05825, STEMCELL Technologies). Briefly, plates were coated with 1.6% growth
factor-reduced Matrigel (356230, BD Biosciences) dissolved in DMEM/F12 (21331-
020, Life Technologies) for 2 h at room temperature. Human ESCs were passaged
by a brief treatment with StemPro Accutase Cell Dissociation Reagent (A11105-01,
Life Technologies). For the first 24 h after passaging 10 μM ROCK inhibitor Y-
27632 (72304, STEMCELL Technologies) was added to the culture. Medium was
replaced on a daily basis.
Human TSCs were cultured in collagen-coated plates. Briefly, plates were coated
with 0.5% Collagen from human placenta (C7521, Sigma) dissolved in PBS for at
least 2 h at 37 C. Human TSC medium contained DMEM/F12 (048-29785, Alpha
Labs) or Advanced DMEM/F12 (12634-010, Thermo Fisher Scientific)
supplemented with GlutaMAX (35050061, Thermo Fisher Scientific), sodium
pyruvate (11360070, Thermo Fisher Scientific), penicillin–streptomycin (15140122,
Thermo Fisher Scientific), 100 μM β-mercaptoethanol (31350-10, Thermo Fisher
Scientific), 0.2% fetal bovine serum (16141-079, Gibco), 0.3% BSA (017-22231,
Wako Chemicals), 1% Insulin–Transferrin–Selenium–Ethanolamine (ITS-X,
51500-056, Thermo Fisher Scientific), 1.5 μg mL−1 L-ascorbic acid (A4403, Sigma),
50 ng mL−1 human EGF (E9644, Sigma), 2 μM Chiron (produced in house, Stem
Cell Institute), 0.5 μM A83-01 (72022, STEMCELL Technologies), 1 μM SB431542
(72232, STEMCELL Technologies), 0.8 mM VPA (227-01071, Wako Chemicals),
5 μM ROCK inhibitor Y-27632 (72304, STEMCELL Technologies). Human TSCs
were passaged by treatment with TrypLE Express Enzyme (12604-021, Thermo
Fisher Scientific) for 12 min at 37 C. Medium was replaced every other day. Cells
were routinely tested for mycoplasma contamination by PCR.
Conversion of human ESCs. To convert human ESCs into post-implantation-like
TSCs we used an available protocol36. Briefly, human ESCs were first plated with
mTeSR in wells pre-coated with 5 µg mL−1 human recombinant vitronectin (VTN-
N; A14700, STEMCELL Technologies) diluted in PBS for 1 h at room temperature.
The following three days, cells were cultured in TeSR-E7 media (05914, STEM-
CELL Technologies) supplemented with 2 µM CYM5541 (4897, TOCRIS), 25 µM
SB431542 (72232, STEMCELL Technologies), and 20 ng mL−1 BMP4 (120-05,
PeproTech), with fresh media changes each day. Next, 50,000 cells were passaged to
wells pre-coated with 1 µg Laminin-521 (LN521, Biolamina) and 3 µgmL−1 VTN-
N diluted in PBS for 1 h at room temperature. Converted TSCs (cTSCs) were
cultured in human TSC media as defined above. Cells were passaged 3–5 times in
their respective media at a 1:4 ratio, with media change every two days, and then
used for experimentation.
Cloning. Cloning procedures were carried out using Gateway technology (Thermo
Fisher Scientific). A PCR was designed to amplify human CDH1-EGFP and to
include 5′ and 3′ attB sites using the following oligos:
CDH1-EGFP FW: 5′ GGGGACAAGTTTGTACAAAAAAGCAGGCTTC
ACCATGGGCCCTTGGAGCC 3′ and CDH1-EGFP RV: 5′ GGGGACCACTTTG
TACAAGAAAGCTGGGTCTTACTTGATCAGCTCGTCCATGC 3′. This
fragment was introduced in a pDONR221 vector (gift of Jose Silva, Stem Cell
Institute, UK) using the BP Clonase II (11789020, Thermo Fisher Scientific), and it
was further subcloned into a TetO-Zeo plasmid (gift of Jose Silva, Stem Cell
Institute, UK) using the LR Clonase II (11791100, Thermo Fisher Scientific).
Human stem cell electroporation. Human ESCs and human TSCs were elec-
troporated with three plasmids: CDH1-EGFP-TetO-Zeo, PB-CAG-rtTA3-puto
(gift of Jose Silva, Stem Cell Institute, UK) and the pBase plasmid expressing the
PiggyBac transposase using the Neon transfection system (Thermo Fisher
Scientific) following the manufacturer’s instructions. The following settings were
used: for human TSCs 1150 V, 20 ms, 2 pulses; for human ESCs 1200 V, 20 ms, 2
pulses. The following antibiotics for selection were added two days after the
transfection: 2 μg mL−1 puromycin (ant-pr-1, Invivogen) and 100 μg mL−1 zeocin
(ant-zn-1, Invivogen). CDH1-EGFP expression was triggered by adding 1 μg mL−1
or 10 ng mL−1 of doxycycline hyclate (D9891, Sigma).
siRNA-mediated knock-down of CDH1 in human TSCs. To knockdown
expression of CDH1 we followed an available protocol for siRNA-mediated loss-of-
function experiments in human TSCs51. First, a solution of 30 pmol of control or
CDH1 siRNA Silencer Select (4392420, assay ID s531135, Thermo Fisher Scien-
tific), 500 µL of OptiMEM media (31985062, ThermoFisher) and 5 µL of Lipo-
fectamine RNAi MAX (13778075, Thermo Fisher Scientific) per well, was
incubated for 10–20 mins at room temperature. Next, 250,000 human TSCs were
plated into a 6-well precoated with collagen in 2.5 mL human TSC media. Then,
500 µL of siRNA mix was added. Two days later, this was repeated. Four days after
the initiation of siRNA-mediated knockdown, samples were processed for down-
stream analyses.
Human embryo and stem cell immunofluorescence staining. To detect protein
expression using immunofluorescence, embryos and stem cells were washed once
with phosphate-buffered saline (PBS) and fixed by incubating them in freshly made
4% paraformaldehyde (PFA, 15710, Electron Microscopy Sciences) at room tem-
perature for 20 min. Embryos and stem cells were then washed three times with
washing solution at room temperature and then permeabilized by incubating them
in either 0.5% (embryos) or 0.3% (stem cells) (vol/vol) Triton X-100 (T8787, Sigma
Aldrich)+ 0.1 M of glycine (BP381-1, Thermo Fisher Scientific) in PBS at room
temperature for 30 min. Then, embryos and stem cells were washed three times
with washing solution (0.1% (vol/vol) Tween 20 (P9416, Sigma Aldrich) in PBS) at
room temperature for 2 min each and incubated in blocking solution (5% (w/vol)
bovine serum albumin (BSA, A9418, Sigma Aldrich) in washing solution) at room
temperature for 1 h. Then embryos and stem cells were incubated with primary
antibodies diluted 1:200 in blocking solution at 4 °C overnight. After washing the
embryos three times in washing solution at room temperature for 2 min, embryos
were incubated with fluorescence-conjugated secondary antibodies, Alexa-
Fluor®488 Phalloidin (A12379, Thermo Fisher Scientific) and DAPI (D3571,
Thermo Fisher Scientific) diluted 1:500 in blocking solution at room temperature
for 2 h. Embryos and stem cells were then washed twice in washing solution at
room temperature for 2 min and imaged. Primary antibodies: mouse monoclonal
anti-ECAD antibody (610182, BD Biosciences, clone 36, 1/100), goat polyclonal
anti-GATA3 antibody (AF2605, R&D Systems, 1/200 dilution), goat polyclonal
anti-GATA6 antibody (AF1700, R&D Systems, 1/200 dilution), rat monoclonal
anti-GFP antibody (GF090R, clone GF090R, Nacalai, USA, 1/1,000 dilution),
mouse monoclonal anti-HLA-G (ab7759, clone MEM-G/1, 1/200 dilution), goat
polyclonal anti-NANOG antibody (AF1997, R&D Systems, 1/200 dilution), mouse
monoclonal anti-OCT3/4 antibody (sc-5279, Santa Cruz Biotechnology, clone C-
10, 1/200 dilution), rabbit polyclonal anti-Phospho-Histone H3 antibody (9701,
Cell Signaling Technology, 1/200), mouse monoclonal anti-Podocalyxin antibody
(MAB1658, R&D, clone 222328, 1/500 dilution), and rabbit monoclonal anti-
Syndecan-1 (ab128936, clone EPR6454, Abcam, dilution 1/100). Secondary anti-
bodies: donkey anti-mouse AlexaFluor®568 (A10037, Thermo Fisher Scientific),
donkey anti-rabbit AlexaFluor®647 (A31573, Thermo Fisher Scientific), and don-
key anti-goat AlexaFluor®488 (A11055, Thermo Fisher Scientific). Stained embryos
were imaged by Leica SP8 confocal scanning microscopy.
Image analysis. Images were analyzed by Fiji Image J (NIH)52. For all quantitative
measurements, laser power and detector gain were maintained constant. Cell
numbers in embryos were manually counted using the Fiji Cell Counter plugin.
Cell numbers in stem cell cultures were automatically counted using the Analyze
Particles tool of Fiji. To quantify immunofluorescence levels in embryos a repre-
sentative single plane capturing the trophoblast was chosen. A region of interest
was defined on the outer rim of trophoblast cells. A cytoplasmic and membrane
mask was created by subtracting the DAPI signal, which was then used to measure
the levels of SDC1 and ECAD. To quantify immunofluorescence levels in stem cells
a binarized image of DAPI was used to create a nuclear mask. This mask was then
applied to the GATA3 or NANOG channels to measure fluorescence intensity.
RNA extraction and RT-PCR. RNA was extracted using TRIzol reagent
(15596010, Thermo Fisher Scientific) following the manufacturer’s instructions.
The reverse transcriptase reaction was performed with 1 μg of RNA in the presence
of random primers (C1181, Promega), dNTPs (N0447S, New England BioLabs),
RNAse inhibitor (M0314L, New England Biolabs) and M-MuLV reverse tran-
scriptase (M0253L, New England BioLabs). RT-PCR reactions were carried out on
a Step One Plus Real-Time PCR machine (Applied Biosystems) using Power SYBR
Green PCR Master Mix (4368708, Thermo Fisher Scientific). A list of all the
primers used is provided in Supplementary Table 3. The following program was
used: 10 min 95 °C denaturation and 40 cycles of 15 s 95 °C and 1 min 60 °C.
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Isolation of genomic DNA from cell lines. To collect DNA from human ES and
TS cell lines for karyotyping, cells from confluent 12- or 6-wells were pelleted and
resuspended in 500 µL TNES buffer (50 mM Tris (B2005, Thermo Fisher Scientific)
pH 7.4, 100 mM EDTA (15575, Thermo Fisher Scientific) pH 8.0, 400 mM NaCl
(27810.262, VWR), 0.5% sodium dodecyl sulfate (SDS)) and 10 µM proteinase K
(19131, Qiagen). The solution was incubated at 55 °C for 1 h. Next, 150 µL of 6 M
NaCl was added, and the solution was centrifuged for 5 min at full speed at 4 °C.
Totally, 500 µL of supernatant was transferred to a new tube and mixed by
inverting with 500 µL of ethanol. Next, the solution was centrifuged for 7 mins at
full speed at 4 °C. The supernatant was aspirated, and the pellet washed with 200 µL
of 70% ethanol. The pellet was airdried for 3–5 min and then resuspended in 50 µL
of TE buffer (10 mM Tris pH 8.0, 1 mM EDTA pH 8.0). This was incubated at
65 °C for 20 min or until the pellet dissolved.
Embryo sample preparation for copy number analysis. Trophoblast biopsies
from blastocysts, or cells dissected from fixed post-implantation embryos were
loaded into PCR tubes, and were lysed in alkaline lysis buffer prepared by adding
6 μl molecular biology grade water into PCR tubes, followed by 1 μl alkaline lysis
buffer [200 mM KOH and 50 mM DTT]. Samples were incubated at 65 °C for
10 min before 1 μl of neutralization buffer [0.9 M Tris–HCl, pH 8.3, 0.3 M KCl and
0.2 M HCl] was added53.
Chromosome copy number analysis by tNGS. tNGS was performed by the
Foundation for Embryonic Competence (FEC, Basking Ridge, NJ, USA). Embryo
lysates were amplified using TaqMan Preamplification Master Mix as recom-
mended by the supplier (ThermoFisher Scientific Inc.) in a 50-µL reaction volume
with 24 cycles (95 °C for 10 min, 24 cycles of 95 °C for 15 s and 60 °C for 4 min,
then 4 °C hold) using an Applied Biosystems 2720 thermocycler, and then quan-
tified with D1k ScreenTape (Agilent Technologies Inc.). Pooled libraries with up to
48 samples were purified utilizing the Agencourt Ampure XP Systems (Beckman
Coulter) as per manufacturer recommendations. Ion sphere particles containing
clonally amplified libraries were prepared, enriched and loaded to each PI chip
using the Ion Chef Instrument (Thermo Fisher Scientific), and then sequenced
using the Ion PI Chip V3 and Ion PI Hi-Q Sequencing Kit on the Ion Proton
instrument (Thermo Fisher Scientific) following manufacturer’s instructions. The
reads were filtered for quality and aligned to the human genome, and the copy
number of each chromosome was determined24.
Chromosome copy number analysis by PCR24. Multiplex amplification of 96
loci (4 for each chromosome) was performed using TaqMan Copy Number Assays
and TaqMan PreAmplification Master Mix as recommended by the supplier
(Thermo Fisher Scientific), and in a 50 µl reaction volume for 18 cycles (95 °C for
10 min, 24 cycles of 95 °C for 15 s and 60 °C for 4 min, then 4 °C hold) using a 2720
thermocycler (Thermo Fisher Scientific). Real-time PCR was performed in quad-
ruplicate for each of the individual 96 loci using TaqMan Gene Expression Master
Mix (Thermo Fisher Scientific) a 5 µl reaction volume, a 384-well plate, and a
ViiA7 real-time PCR system, as recommended by the supplier (Thermo Fisher
Scientific). A unique method of the standard delta–delta threshold cycle (ΔΔCT)
method of relative quantitation was applied to assess the copy number of individual
chromosomes25.
Chromosome copy number analysis by SNP microarray. Whole-genome
amplification (WGA) was performed on the lysate according to the manu-
facturer’s instructions starting with library preparation and using the WGA4
GenomePlex Single Cell Whole Genome Amplification kit (Sigma-Aldrich). The
GeneElute PCR Purification kit was used to purify WGA DNA from each reac-
tion (Sigma-Aldrich). The WGA or genomic DNA was processed for analysis on
the 262 K NspI single-nucleotide polymorphism (SNP) genotyping array as
recommended by the supplier (Affymetrix Inc.). Hybridization, washing, stain-
ing, and scanning were conducted with the GeneChip Hybridization Oven 640,
GeneChip Fluidics Station 450, and GeneChip Scanner 7G, respectively, and as
recommended by the manufacturer (Affymetrix). Copy number assignments and
loss of heterozygosity analysis results were obtained using the Copy Number
Analysis Tool 4.0.1 (Affymetrix). The reference data set consisted of 30 normal
female genomic DNA samples.
Statistical analyses. Statistical analyses of post-implantation embryo development
and stem cell experiments were done in GraphPad Prism. Sample size was deter-
mined based on previous experimental evidence. Researchers were not blind to
embryo genotype. Qualitative data are presented as a contingency table and were
analyzed using a chi-square test. Quantitative data are presented as mean ± s.e.m.
with all data points displayed. The normality of the data was analyzed using a
D’Agostino-Pearson omnibus normality test, and potential significant differences
in the variances were assessed. Data with a Gaussian distribution was analyzed
using an unpaired two-tailed Student’s t test or a two-tailed ANOVA test with
Tukey’s multiple comparison test. Data that did not present a Gaussian distribution
was analyzed using a two-tailed Kruskal–Wallis test with Dunn’s multiple
comparison test.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
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